WHIPPANY, N.J., Jan. 26 /PRNewswire/ -- Adding to its strong executive team, Halo Pharmaceutical today announced the addition of Allen M. Rosenston, a thirty-five year pharmaceutical industry veteran, as Halo's new Vice President of Business Development. Al comes to Halo from a long and distinguished career at Abbott Laboratories where he held diverse roles in operations, business development, and related business functions. "The addition of Al to the Halo business development team is a significant achievement. Al has deep experience within the pharmaceutical industry. He developed Abbott's domestic Contract Pharmaceutical Manufacturing Business Unit and, at the time of his retirement, he was responsible for the global finished goods contract manufacturing business," according to Mohd Asif, Halo's Chief Financial Officer.
Al comes to Halo shortly after Halo's acquisition of its Whippany, NJ facility, a facility which has been producing various dosage forms for 35 years. "I am thrilled to be part of the Halo Pharmaceutical team, and to build on the legacy of this outstanding facility and group of talented people with an average seniority of over 20 years. Based on my discussions with the new Halo team, this is a unique opportunity to create a world-class pharmaceutical services company right in the heart of New Jersey. Maintaining focus on quality, service, and compliance, along with the flexible manufacturing capabilities of the Whippany facility, will create a high-level of interest with prospective customers. I anticipate us to be highly competitive when overall service value is assessed."
Halo capabilities include an impressive array of formulation services, operations for the aseptic filling of topical ointments, solid dosage forms (tablets and capsules), liquids, suppositories, associated packaging (tablet, powder, liquids and HUD) and ample laboratory space for formulation development, pre-clinical and clinical supplies and support of commercial operations. An additional asset is the site's capability to manufacture controlled substances (C2-C5) and an API manufacturing unit with an outstanding track-record of meeting DEA requirements.
Al joined Halo on January 5, 2009, and can be reached at arosenston@halopharma.com or at 973-428-4087.
About Halo Pharmaceutical
Halo Pharmaceutical, headquartered in Whippany, NJ, is a full-service, specialty pharmaceutical company, offering state-of-the-art contract manufacturing, early stage formulation development and laboratory services to the pharmaceutical and related industries. Halo is currently a supplier of choice to a number of large and medium size brand pharmaceutical companies for important lifecycle products. Contract manufacturing capabilities include the ability to conduct aseptic filling, granulation, blending, tableting, coating, packaging, and related warehousing operations. Halo Pharmaceutical is a privately-held company.
CONTACT: Douglas K. Kollmorgen, President, +1-973-428-4011,
dkollmorgen@halopharma.com, or Mohd Asif, Chief Financial Officer,
+1-973-428-4013, masif@halopharma.com, both of Halo Pharmaceutical
Web site: http://www.halopharma.com/
